Abstract: Sarcomas are defined as malignant neoplasms derived from mesenchymal tissues. A variety of different molecular approaches, including gene expression profiling, have identified candidate biomarkers and insights into sarcoma biology that will aid in the diagnosis and treatment of these tumors. Many gene expression profiling findings have been translated into immunohistochemical tests for diagnostic, prognostic, or predictive purposes. This review details gene expression studies done in 3 sarcomas, synovial sarcoma, gastrointestinal stromal tumor, and leiomyosarcoma.
1
Sarcomas can be broadly classified into groups based on their genomic complexity and our knowledge to date. 2 There are a number of diagnostic entities for which known pathognomic molecular events such as translocations and gene mutations have been described. The number of diagnostic entities in this category is quite large, perhaps larger than in any other cancer type, and can represent a morphologic diagnostic challenge for pathologists. This is especially daunting if the pathologist does not have access to the newer diagnostic approaches such as fluorescence in situ hybridization, in some instances, to confirm the morphologic impression.
A variety of different molecular approaches, including gene expression profiling, have identified candidate biomarkers and generated insights into sarcoma biology that will aid in the diagnosis and treatment of these tumors. These new biomarkers may act as surrogate markers for genomic features and yet require simpler methodology that most laboratories have access to, like immunohistochemistry.
The most common sarcomas, however, are not included in the group that can be described by translocations and gene mutations. Rather, the most common sarcomas have complex karyotypes and pleomorphic histology and lack identifiable molecular events. The least progress in sarcoma research has been made in these tumors. Although it is tempting to declare that these tumors are poorly differentiated or undifferentiated representations of tumors with no conserved molecular and morphologic features, there is little evidence to suggest that this is the case. It is possible that this group of sarcomas is analogous to the more common carcinomas in terms of both genomic and phenotypic complexity. This comparison gives us hope. Considerable research effort has demonstrated that a number of carcinomas, such as breast, can be classified into different groups based on gene expression and DNA copy number profiles. Moreover, these new groupings have clinical pathologic correlations that can impact patient care. 3 The difference in progress between the poorly defined sarcomas and carcinomas may in part be due to the differences in project design. The difference in specimen numbers between sarcoma and carcinoma projects can often be between 5 and 10 folds. This difference in power dramatically affects the ability of a study to identify distinct subgroups and, by extension, recurrent alterations at the molecular level. Although these differences are bad enough, there is an additional complexity in that most carcinoma studies are restricted to a single organ system whereas most of the sarcoma studies, being challenged for specimen accrual, involve sarcomas from a wide variety of anatomic locations that may not be biologically related.
Because of the mixture of tumors with pathognomic molecular events, tumors that are as yet undefined, and emerging pharmaceuticals that can target specific gene events, it is an exciting time in the field of soft tissue tumor clinical research (''translational research''). Larger, more sophisticated expression profiling studies should continue to make clinically relevant observations in sarcomas. Discoveries in the biology of these tumors 4, 5 can be quickly translated into new and effective therapies. All these occur in the backdrop of traditional treatment options including surgery, chemotherapy, and radiotherapy, which are improving as well, especially as it is increasingly recognized that a comprehensive multimodality approach can be very effective.
GENE MICROARRAY EXPRESSION PROFILING
Genome-wide gene expression profiling has been used for cancer research for over a decade. 6 The fundamental chemistry involves the hybridization of complementary sequences of the sample RNA with nucleic acid spotted on a slide, chosen to represent a gene or region of interest. The sequence of the spotted nucleic acid is selected based on carefully considered physical parameters to increase the likelihood that the hybridizing RNA is the true intended target. Nevertheless, a variety of artifacts, such as crosshybridization can lead to poor data. The broad objectives of gene expression profiling in sarcomas have been to identify driver genetic changes and pathways, to modify the classificatory scheme for sarcomas and improve our diagnostic, prognostic, and predictive tools. The latter goals have focused on the identification of biomarkers, typically via immunohistochemistry, to augment diagnosis, patient outcome prediction, and determination of response to therapy.
Gene microarray expression profiling of soft tissue tumors has been limited by the scarcity of fresh frozen tumors, the large number of pathologically recognized types, and the cost of supplies and labor. As a result, most studies of gene expression profiling have examined relatively small numbers of soft tissue tumors per type (3 to 10 cases) while profiling tens of thousands of genes. As these techniques produce a tremendous amount of data for a single sample, new statistical approaches are required to determine the significance of the observed findings and narrow down which findings to pursue. As the microarray technologies have improved, generating larger datasets with improved data quality, the downstream statistical analyses have also matured providing a series of approaches for researchers working with these technologies as well as recommendations to facilitate standardization of the primary steps of microarray data analysis. 7 
TISSUE MICROARRAYS: EXTENDING AND CONFIRMING GENE EXPRESSION PROFILING OBSERVATIONS
Often, the next challenge is to identify genes that are good candidates for further analysis given that it is impractical to analyze in depth more than a handful of genes. Typically, several hundreds of genes will show significant variation in expression levels between different sarcomas even when limited numbers of cases are profiled. If candidate assessment must occur on a gene-by-gene basis, it is advantageous to simultaneously assess hundreds of tumors as can be done with a tissue microarray approach. Conventional biology techniques (such as Western blotting) are not amenable to such sample scale.
Protein expression using immunohistochemistry or messenger RNA levels using in situ hybridization can be investigated for candidate genes on a gene-by-gene basis by conducting these assays on tissue microarrays that contain hundreds of specimens of the tissues of interest. 8 Tissue microarrays are a collection of different tissues (or tumors). The physical array is composed of a deep block of paraffin with an organized array of cores of tissue typically ranging between 0.6 and 2 mm. A total of 100 to 200 slides of 4 to 5 mm thickness can be derived from a block. Thus, gene array analysis of tens of tumors can focus our attention on a large number of genes that is still relatively large (hundreds to thousands), whereas tissue microarray analysis allows for in-depth study of expression of selected genes (tens) across a much larger number of tumors (hundreds). 10 the field of immunohistochemistry is still advancing. For example, multiple antibody stains on a single slide using different reporter dyes are now used in a number of clinical applications and can be useful in identifying relationships between 2 different cell types (eg, prostatic luminal and basal cells) or a subgroup of a single cell type (eg, proliferating melanocytes).
ADVANTAGES OF IMMUNOHISTOCHEMISTRY IN CLINICAL APPLICATION
One limitation is that immunohistochemistry requires expert interpretation. Another limitation is that it is difficult to control for variation in tissue quality or stain quality. This is a real problem while dealing with clinical specimens as fixation and tissue processing can be quite variable and may lead to false negative results. However, a negative result does not mean that the protein target is not there and clinically targetable, as seen in KIT immunohistochemistry negative gastrointestinal stromal tumors (GISTs), which bear an imatinib-sensitive KIT gene mutation and response to imatinib. 11, 12 An immunohistochemical panel rather than a single biomarker approach is the most clinically robust approach.
Morphology often supplies the necessary backup to a single biomarker but very poor tissue preservation is recognizable in the histology laboratory when the tissue is cut for slides but can be identified by light microscopy. This typically represents underfixation. More subtle tissue degradation is due to overfixation, which preserves the tissue architecture but destroys the macromolecules due to extensive cross-linking. 13 We have dealt with this issue using an oligo dT probe that identifies the presence of all poly-adenlyated (polyA) RNAs (mRNA). Oligo dT probes are typically used as controls for RNA in situ hybridizations used for some viral genes (eg, Epstein-Barrencoded RNA in Epstein-Barr virus). RNA quality is the most sensitive macromolecule to poor tissue preservation (compared with protein and DNA) and gets degraded quickly (Figs. 1A-C). Thus, it can be used as a ''canary in the coal mine'' to identify tissues, which may not have good protein preservation.
Rather than summarizing the expression profiling work for all sarcoma types in a superficial manner, this review will look closely at 3 sarcomas to illustrate 
SYNOVIAL SARCOMA
Synovial sarcoma is a soft tissue sarcoma characterized by a translocation involving chromosomes 18 and chromosome X, which results in a fusion of genes SS18 (SYT) and SSX.
14 Clinical tests demonstrating the presence of either the chromosomal translocation or the fusion product by cytogenetics, fluorescence in situ hybridization, or reverse transcriptase gene reaction are generally accepted as the definitive method of diagnosis. 15 However, these methods are not easily performed or readily available for a number of laboratories. The differential diagnosis includes malignant peripheral nerve sheath tumor, solitary fibrous tumor, hemangiopericytoma, and fibrosarcoma, and, less likely, small round blue cell tumors. The current immunohistochemical markers to identify synovial sarcoma include cytokeratins, epithelial membrane antigen, and CD34. However, these markers are not ideal in terms of sensitivity and specificity.
Several groups have performed gene expression profiling studies involving synovial sarcomas either in a large group of heterogeneous soft tissue neoplasms or as a discrete set of cases in a limited differential diagnosis. Gene expression profiling studies involving over 80 synovial sarcomas have identified TLE1 as a transcript that highly discriminates between synovial sarcoma and other soft tissue tumors. [16] [17] [18] [19] TLE1 was not well measured in one of the first studies of sarcomas including synovial sarcoma. 20 This highlights the potential variations in measurements between different platforms, in this case, Stanford cDNA microarrays.
In a continuation of these observations, Nielson et al surveyed the expression of the TLE1 protein across a large set of soft tissue tumors and found that TLE1 immunohistochemistry is highly sensitive for synovial sarcoma (Fig. 1D) and is reasonably specific, demonstrating moderate staining in few schwannomas and solitary fibrous tumors/hemangiopericytomas. 21 This study suggested that a TLE1 antibody is a robust biomarker for synovial sarcoma and may be useful in clinical practice. A second study examined the expression of TLE1 in standard, full cross-section slides of soft tissue and bone tumors. 22 This included 20 synovial sarcomas and 143 other mesenchymal neoplasms. Consistent with the initial tissue marker array study, the vast majority of synovial sarcomas (18/20) demonstrated TLE1 expression. TLE1 expression was also seen in 25% to 37% of nonsynovial sarcoma neoplasms. This included tumors such as neurofibromas, schwannomas, and malignant peripheral nerve sheath tumors commonly observed in the differential diagnosis. The conclusions drawn from this study were that TLE1 may be a useful diagnostic marker but in the context of a larger immunohistochemistry panel. On the basis of these results, it appeared that the gene expression studies overestimated the specificity.
However, a third study that prospectively evaluated a series of consecutive soft tissue tumors with the differential diagnosis including synovial sarcoma found slightly different results. 23 This study, conducted in the clinical setting, used TLE1 and a panel of other immunohistochemical markers including BCL1, epithelial membrane antigen, and cytokeratin. TLE1 demonstrated high sensitivity in 35 synovial sarcoma cases that were subsequently confirmed by molecular techniques and no reactivity with the other 73 soft tissue tumors. Compared with other immunohistochemical biomarkers, TLE1 was more sensitive and specific for synovial sarcoma.
The aggregate of these findings highlight 2 difficulties encountered in biomarker generation from the data derived from gene expression profiling. The first involves the conversion of RNA expression as identified by gene expression profiling to protein expression as identified by immunohistochemistry. There are both technical and biological reasons why there is not a linear correlation. On a biological level, although gene expression is often controlled at the transcriptional level within the nucleus, a number of genes have significant gene product control at posttranscriptional steps including half-life of the RNA transcript, translation into protein product, and posttranslational modifications. There are also technical reasons why the observed transcript level may not correlate with the protein level. In part this relates to the large number of observations and variables that go into making these measurements. However, an equally important aspect of this relates to the variability inherent with performing immunohistochemistry on clinical specimens. Although immunohistochemistry is often reported out as either positive or negative, the reality of the protein expression is that expression of a single gene product exists on continuity from high to low. The thresholds set by immunohistochemistry as defined by methodological features such as titer can make it appear that expression is binary or at worst defined by a small number of categories (negative, weak positive, strong positive). This is not the reality for most biological instances.
GASTROINTESTINAL STROMAL TUMOR
GISTs are neoplasms that occur in close association with interstitial cells of Cajal. Most of these tumors are characterized by mutations in either KIT or platelet-derived growth factor receptor, alpha polypeptide (PDGFRA). 24 These receptor tyrosine kinases can be targeted by small molecule inhibitors with dramatic clinical effects. 25 Several large gene expression profiling studies have included a substantial number of GISTs. Three early gene expression profiling studies, in particular, previously identified KIT and some of its downstream signaling targets and a new candidate biomarker using a total of 26 GISTs compared with 179 other soft tissue tumors. 19, 20, 26 Among the novel biomarkers identified were DOG1 (aka ANO1 and TMEM16A) and protein kinase C-theta. DOG1 was initially identified in these studies as a hypothetical gene, FLJ10261, and rabbit antisera made against small polypeptides from the predicted sequence rated strong reactivity for 136 out of 139 GISTs. 5 Of the remaining 438 non-GIST cases, only 4 were immunoreactive for DOG1. In the same study it was found that GISTs with a mutation in PDGFRA were consistently positive with the DOG1 antibody while most of these tumors failed to react with KIT antibody. A number of additional gene biomarker candidates identified by gene expression profiling studies did not show good sensitivity or specificity by either immunohistochemistry or RNA in situ hybridization.
An anti-DOG1 monoclonal antibody (Fig. 1E ) has since been made and has also been found to be a sensitive and specific marker for GISTs. 27 The sensitivity of this antibody is apparently slightly lower than in the polyclonal antibody (87% of scorable GISTs). However, the specificity is possibly better with this antibody. This marker also turns out to be a selective marker of interstitial cells of Cajal in the GI tract. 28 While interstitial cells of Cajal express KIT, this is also expressed on mast cells, occasionally making the distinction between the 2 cell types problematic. The monoclonal antibody to DOG1 efficiently stains interstitial cells of Cajal throughout the GI tract and does not label mast cells. The complementary relationship between gene expression profiling and immunohistochemistry and tissue microarrays is clear when we consider that observations on 54 GISTs (only 8 cases if the first study is only considered) by gene expression profiling lead to the discovery of a biomarker candidate that is subsequently tested on over 2000 cases. 27, 29, 30 A number of follow-up studies have either demonstrated or failed to demonstrate a benefit in using DOG1 over KIT in the diagnosis of GISTs. 29, 30 From a diagnostic pathology perspective, straightforward GISTs may require only 1 GIST biomarker. However, atypical GISTs may be described in 2 categories. One group of GIST consists of cases for which biomarker labeling for any of the 3 biomarkers is poor. This may be due to biological or technical features. A second group includes GISTs in unusual clinical presentations. This may include cases with unusual morphology or cases in unusual locations. In these instances, it seems reasonable to confirm the morphologic impression using multiple biomarkers. This would help guard against the possibility of accidentally identifying a non-GIST that routinely stains with a perceived GIST biomarker (such as melanoma with KIT).
The cost of misdiagnosing a GIST far outweighs the cost of performing the additional immunohistochemical stain. The benefits of an additional marker for the diagnosis of GISTs become clear when the totality of care for these patients is considered. Patients with GISTs that are responsive to receptor tyrosine kinase targeting typically receive this drug for several years at great expense. Thus, the small cost and effort of precisely determining the likely response to gene-targeted therapy in these instances, by performing DOG1 and KIT immunohistochemistry followed by mutation analysis performed by gene sequencing, is insignificant compared with the overall care of the patient. These additional markers play an important role for patients who do not have GISTs, as other therapeutic modalities can be tried sooner. In addition, though gene sequencing for mutation analysis is not widely available in hospitals, it would seem to be a very wise use of resources given the expense of subsequent clinical intervention to identify cases which will in fact respond to small molecule inhibitor therapy. 25 There have been 2 studies that have looked at gene expression profiling differences within GISTs with regard to mutation subtypes. 31, 32 A total of 54 GISTs with differing activating mutations in either KIT or PDGFRA were examined. A number of genes were found to be significantly differentially expressed within these mutation subgroups. However, the expression differences between GISTs with different mutations are not nearly as striking as differences between GISTs and non-GISTs. Nevertheless some of these identified genes have been further evaluated for potential biological interest. To date, none of these genes have been rigorously tested as biomarkers for differentiating between different types of mutations within GISTs. This may in part be in due to the relative ease and definitive output of gene sequencing for the mutation status.
Protein kinase C-theta is also a gene identified as highly expressed in GISTs compared with other soft tissue tumors in these gene expression profiling studies. Initial studies suggested that this marker was highly expressed in GISTs and rarely expressed in other GI mesenchymal tumors and various KIT positive tumors. 33, 34 The determination of utility of the marker in the clinical setting and in combination with other GISTs is still in progress.
LEIOMYOSARCOMA
Leiomyosarcomas are mesenchymal neoplasms with varying degrees of smooth muscle differentiation that typically demonstrate complex karyotypes. 35 These tumors represent a stark contrast from GISTs and synovial sarcomas in that the diagnostic criteria do not extend to the molecular level. Although most GISTs and synovial sarcomas have well-defined anatomic locations, morphologic features, immunohistochemical phenotypes, and/or definitive genomic changes, leiomyosarcomas are defined by a spectrum of morphologic features and only a few immunohistochemical biomarkers that may also be expressed in other soft tissue tumors. The overlap between leiomyosarcomas and other sarcomas with complex alterations and typically high-grade features, has been noted to be great and numerous.
Researchers have attempted to define different classification schemes for these and other similar tumors. A number of gene expression profiling studies have been performed on leiomyosarcoma; however, most of them have involved less than 20 cases. These small numbers make the realization of clinical subtypes very difficult. Three studies have identified subsets of leiomyosarcomas that express distinct gene expression patterns. [36] [37] [38] The group recognized by all of these studies demonstrates high expression levels of muscle-associated genes (eg, ACTG2, CASQ2, CLF2, MYLK, and SLMAP) (Fig. 1F) . These include traditional markers used to define leiomyosarcomas in the clinical setting (desmin and smooth muscle actin) but also include a set of additional markers that may eventually prove to be useful biomarkers for this specific subgroup. Perot et al identified a common amplicon involving MYOCD on chromosome 17, which may be preferentially found in the muscle-specific subgroup. MYOCD is an SRF transcription cofactor that regulates smooth muscle differentiation. In addition to its role in smooth muscle differentiation, MYOCD may confer some oncogenic properties such as cell migration. Despite the number of ''muscle differentiation markers'' present in this subtype of leiomyosarcoma, there is no significant association with grade for these tumors or mitotic count. However, in a multivariate analysis, these tumors did demonstrate a statistically significant favorable outcome in a multivariate analysis including site, mitotic figures, grade, necrosis, and CSF1 stromal response signature. 37 
NEW APPROACHES
We have been using microarrays for gene expression profiling of soft tissue tumors since the turn of the millennium. These studies have been successful in identifying new biomarkers and candidate gene targets, but have had only moderate success in identifying new subtypes of cancer. This is in part due to the success of surgical pathologists who have previously identified, through morphologic features, a wide spectrum of sarcomas. These categories have correlated well with our emerging understanding of the biology and molecular properties of these tumors. Unfortunately, the most common sarcomas generally do not fall into this category. Tumors such as pleomorphic sarcoma (also known as malignant fibrous histiocytoma) and leiomyosarcoma comprise the bulk of adult mesenchymal neoplasia of the malignant variety and have not been well subtyped. This contrasts with the success achieved in other tumor classes such as breast cancer and prostate cancer. In these studies, microarray approaches have identified new diagnostic classes of tumors and demonstrated a commonality in biology and molecular features (for example gene copy number changes). There may be an inherent biological complexity that prevents us from making similar headway with pleomorphic sarcoma and leiomyosarcoma. However, an alternative possibility is that the studies in these sarcomas to date have been limited by practical shortcomings. Specifically, the rarity of these mesenchymal tumors results in the fact that most of the cases are only available in archival material (formalin-fixed, paraffin-embedded). Despite best efforts, the accuracy of microarray studies on this archival material is relatively poor. In these archival specimens, the nucleic acid has been damaged by the formaldehyde resulting in significant fragmentation of the nucleic acid and cross-linking to other macromolecules. These changes in the nucleic acid result in core and aberrant hybridization of the sample nucleic acid to the spotted microarray nucleic acid. These problems significantly diminish the signal to noise ratio. 
MULTIPLEX RT-PCR
A more sophisticated approach with older technologies (for example multiplex PCR) and the development of new technologies, such as high-throughput sequencing, provide a number of solutions to this problem of our inability to accurately profile large numbers of high-grade sarcomas. Multiplex PCR has been recently shown to be robust in archival material and able to provide more and more precise information than immunohistochemistry. 9 Number of examples already exists in other organ systems, such as breast cancer. In breast cancer, a multiplex kit is already available for clinical use in the prognosis of primary breast cancers. In addition, multiplex RT-PCR has been demonstrated to characterize breast carcinomas into their molecular subtypes better than immunohistochemistry. 9 
DASL
Whereas multiplex RT-PCR is useful in analyzing the expression levels of a small number of genes, other molecular solutions allow the analysis of thousands of genes. An example of this is DASL (cDNA-mediated immune, selection, extension and ligation). 39 This method uses a 2-probe oligonucleotide pair to measure each cDNA target. DASL uses 2 small oligonucleotides plus 1 to 20 nucleotides apart on the annealed target cDNA. An extension and ligation step joins these 2 oligonucleotides and the ligation represents identification of the presence of the target RNA. This technique provides good sensitivity, reproducibility, and accuracy for measuring RNA in archival material. It also seems to be amenable to large numbers of samples. The drawback is that the probe pairs must be synthesized and as a result a limited number of gene probe pairs are available for target interrogation.
RNA-SEQ FOR ARCHIVAL MATERIAL: 3SEQ
RNA-seq refers to the methods that use next generation sequencing to generate a measurement of the relative number of transcripts from each gene in a sample. A typical RNA-seq experiment generates several million sequencing reads from a random sample of reverse-transcribed and properly linkered mRNA/cDNA molecules (the library). Expression levels of all genes are determined in parallel, by mapping (aligning) all reads to the genome or transcriptome, and counting how many reads have mapped to any given transcript.
We designed a novel RNA-seq protocol, 3SEQ (3 0 -end Sequencing for Expression Quantification) to specifically work with mRNA extracted from formalin-fixed, paraffinembedded archival tissue. 40 As noted above, archival tissue does not generally lend itself to microarray analyses. However, the small RNA fragments purified from archival tissue, typically in the range of 100 to 500 nucleotides, are ideal for generating small libraries for short read sequencing. Degraded mRNA can be isolated by polyA selection, and then short sequence reads can be obtain from the 5 0 -end of the fragments. These cDNAs are short but contain just enough unique sequence on their 5 0 -ends to be mapped to the reference genome. Transcript counts are thus obtained from a short region, usually in the 3 0 -UTR abutting the polyA tail, giving a convenient aggregation of signal that increases the power of the subsequent statistical analysis (Fig. 2 ). An additional advantage is that, unlike microarray profiling that predefines which transcripts will be measured by choices made in the spotting of sequences in the array construction, 3SEQ generates reads from all polyA RNA molecules including those from unannotated genes and alternative 3 0 UTRs. A more subtle difference is that 3SEQ is sequencing-based. 3SEQ output relies on the availability of the polyA tail for hybridization, the ability of the reverse transcriptase and PCR polymerase to synthesize the RNA sequence, and the ability to form RNA breaks close to the 3 0 end of the RNA. The 3SEQ method represents a different physical measurement than microarrays or DASL, which rely on hybridization of specific nucleic acid sequences, which may have sequence-dependent variations in hybridization. Although comparisons between 3SEQ and microarray profiling show that there are correlations between platforms, there are significant differences in measurements for some genes. This likely means that these different datasets can be mined for new genes that are significant to sarcoma biology, diagnosis, prognostication, and prediction.
The 3 general methods outlined here will likely fulfill different niches. It can be expected that they will impact the field of sarcomas in diagnosis, prognosis, and prediction as archival specimens can now be studied.
CONCLUSIONS
The extensive gene expression research done with sarcomas has yielded a large body of data that should still be mined further but it has already led to clinically relevant tools for diagnosis and treatment (Table 1) . There are still a number of sarcomas, especially the higher-grade genomically complex, adult neoplasms that would benefit from larger profiling studies with clinicopathologically well-annotated specimens. With the rapid development of sequencing technologies, it is unclear how this will be done. More sophisticated bioinformatic analysis may also draw new connections between sarcomas and other medical data. 50 
